New guinea pig model of cryptococcal meningitis

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 8, 2007, Pages 3011-3013

  Kirkpatrick, William R ^a,c   Najvar, Laura K ^a   Bocanegra, Rosie ^a   Patterson, Thomas F ^a,b   Graybill, John R ^a,b  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE; TRIAMCINOLONE ACETONIDE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CEREBROSPINAL FLUID CULTURE; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCUS NEOFORMANS; DISEASE COURSE; DRUG EFFICACY; GUINEA PIG; IMMUNE DEFICIENCY; MALE; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; FLUCONAZOLE; GUINEA PIGS; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; PYRIMIDINES; TRIAZOLES;

EID: 34547646541     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00085-07     Document Type: Article

References (9)

1. Graybill, J. R., and S. R. Kaster. 1984. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191. Am. Rev. Respir. Dis. 129:292-295.
2. Graybill, J. R., L. K. Najvar, G. M. Gonzalez, S. Hernandez, and R. Bocanegra. 2003. Improving the mouse model for studying the efficacy of voriconazole. J. Antimicrob. Chemother. 51:1373-1376.
3. Kirkpatrick, W. R., R. K. McAtee, A. W. Fothergill, M. G. Rinaldi, and T. F. Patterson. 2000. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob. Agents Chemother. 44:2865-2868.
4. Larsen, R. A., M. Bauer, J. M. Weiner, D. M. Diamond, M. E. Leal, J. C. Ding, M. G. Rinaldi, and J. R. Graybill. 1996. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob. Agents Chemother. 40:2178-2182.
5. Najvar, L. K., R. Bocanegra, and J. R. Graybill. 1999. An alternative animal model for comparison of treatments for cryptococcal meningitis. Antimicrob. Agents Chemother. 43:413-414.
6. Odds, F. C., M. Oris, P. Van Dorsselaer, and F. Van Gerven. 2000. Activities of an intravenous formulation of itraconazole in experimental disseminated Aspergillus, Candida, and Cryptococcus infections. Antimicrob. Agents Chemother. 44:3180-3183.
7. Patterson, T. F., P. Miniter, J. Dijkstra, F. C. Szoka, Jr., J. L. Ryan, and V. T. Andriole. 1989. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J. Infect. Dis. 159:717-724.
8. Perfect, J. R., and D. T. Durack. 1982. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J. Infect. Dis. 146:429-435.
9. Saag, M. S., W. G. Powderly, G. A. Cloud, P. Robinson, M. H. Grieco, P. K. Sharkey, S. E. Thompson, A. M. Sugar, C. U. Tuazon, J. F. Fisher, N. Hyslop, J. M. Jacobson, R. Hafner, W. E. Dismukes, the NIAID Mycoses Study Group, and the AIDS Clinical Trials Group. 1992. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N. Engl. J. Med. 326:83-89.